filmov
tv
Selexipag Benefit Based on Time of Diagnosis
Показать описание
How new GRIPHON data showed further definitive long-term outcomes for patients with PAH.
HCPLive
pulmonary hypertension
ATS
PAH
Рекомендации по теме
0:02:04
Selexipag Benefit Based on Time of Diagnosis
0:00:34
Early selexipag initiation and long-term outcomes: insights from randomised controlle... | RTCL.TV
0:00:54
'Fundamentally, the decision on Selexipag is wrong'
0:03:23
GRIPHON Study on Selexipag - Review
0:52:18
Pulmonary Arterial Hypertension Diagnosis, Classifications and Therapy
0:04:55
How to use Uptravi - Explain Uses,Side Effects,Interactions
0:03:36
Uptravi (selexipag) - Drug Rx Information
0:06:27
Selexipag: How is it used? Who is it for?
1:41:25
Selepeg MSN Webinar
0:27:50
Oral Prostacyclins in the Treatment of PAH
0:05:52
The power of the patient voice: Dr David Kiely and Dr Neil Hamilton
0:11:48
15 (17 0ct) Selexipag
0:01:01
Week 2 of Uptravi for Pulmonary Arterial Hypertension with Mixed Connective Tissue
1:22:31
Selepeg MSN Webinar
1:20:26
MSN Pro Live Webinar 4th March 2022 | Every Stage of Pulmonary Arterial Hypertension| Selexipag
2:18:01
Selepeg MSN Webinar 2022
0:06:43
How Do You Titrate the Dose of PH Medications to Maximize Efficacy and Avoid Side Effects?
0:05:11
What Are the Concerns and Issues for Practitioners and Patients in Managing Medication Side Effects?
0:20:33
Dr Arora Chapter 3 Treating With Uptravi
0:01:13
Dr Arora Uptravi Pre amble
0:00:51
Day Four of Uptravi for Pulmonary Arterial Hypertension with Mixed Connective Tissue
0:05:06
Selexipag
0:00:16
Day 3 of 800 micrograms of uptravi for pulmonary arterial hypertension & mixed connective tissue
0:01:01
Uptravi final dose report - very positive!
visit shbcf.ru
0:02:04
0:00:34
0:00:54
0:03:23
0:52:18
0:04:55
0:03:36
0:06:27
1:41:25
0:27:50
0:05:52
0:11:48
0:01:01
1:22:31
1:20:26
2:18:01
0:06:43
0:05:11
0:20:33
0:01:13
0:00:51
0:05:06
0:00:16
0:01:01